Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir
Final published version, 293 KB, PDF document
Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822.
Original language | English |
---|---|
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
Volume | 73 |
Issue number | 3 |
Pages (from-to) | e811-e814 |
ISSN | 1058-4838 |
DOIs | |
Publication status | Published - 2021 |
Bibliographical note
Publisher Copyright:
© Crown copyright 2021.
- ART, HIV, NAFLD
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
No data available
ID: 279274657